

03rd November, 2018

The Manager – Listing Dept.,
 National Stock Exchange of India Ltd.,
 Exchange Plaza, 5th Floor,
 Plot No. C/1, G. Block,
 Bandra - Kurla Complex, Bandra (E),
 Mumbai – 400 051
 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub: Compliances under Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for half year ended 30th September, 2018

In continuation to our letter dated 03rd November, 2018, submitting the Financial Results of the Company for the quarter and half year ended on 30th September, 2018, please find below the NCD payment Schedule and credit rating as required under Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) with respect to Company’s privately placed secured non convertible debentures:

S r N o	ISIN Number	Previous due date		Next due date & Interest/ Redemption Amount				Credit Rating
		Princ ipal	Intere st	Principal Amount	Payme nt date	Interest Amount	Payme nt Date	
1	INE685A 07033	-	22- Jun-18	83,00,00,000	24-Jun- 19	7,67,78,411.30	24-Jun- 19	ICRA AA Stable
2	INE685A 07041	-	22- Jun-18	83,00,00,000	24-Jun- 20	7,67,78,411.30	24-Jun- 19	ICRA AA Stable
3	INE685A 07058	26- Mar- 18	26- Mar- 18	91,20,00,000	25- Mar-19	13,65,20,942.4 7	25-Mar- 19	ICRA AA Stable
4	INE685A 07066	-	13- Dec-17	100,00,00,00 0	13- Dec-18	39,75,00,000	13-Dec- 18	ICRA AA Stable
5	INE685A 07074	-	29- Dec-17	1,66,65,00,0 00	28- Dec-18	38,89,30,000	28-Dec- 18	ICRA AA Stable
6	INE685A 08015	-	-	500,00,00,00 0	29- Nov-18	34,52,05,479.4 5	29- Nov-18	IND A1+
7	INE685A 07082	-	-	142,86,00,00 0	13- Dec-19	As per coupon reset	14-Dec- 18	ICRA AA Stable

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126



Principal & Interest has been paid on or before the due dates.

Further, please find enclosed herewith the certificate received from IDBI Trusteeship Services Limited, Debenture Trustee as per Regulation 52(5) of Listing Regulations stating that they have taken note of the relevant information pertaining to the half year ended on 30th September, 2018.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

No. 7325/ITSL/OPR/2018-19

November 03, 2018

To,
Torrent Pharmaceuticals Limited,
Torrent House,
Off Ashram Road,
Ahmedabad 380009,

Dear Sir,

Sub: Letter from Debenture Trustee pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR 2015)

This has reference to the privately placed Unsecured/Secured, Non-Convertible Debentures issued by **Torrent Pharmaceuticals Limited** (“**Issuer**”) wherein IDBI Trusteeship Services Limited is acting as the Debenture Trustee and listed on the National Stock Exchange of India Ltd. (NSE) and/or Bombay Stock Exchange (BSE) (“**Listed Debt Securities**”).

Pursuant to Regulation 52(4) read with Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) 2015, the Issuer is required to submit the documents required there along with its half yearly/annual financial results to the Stock Exchange, with a letter of the Debenture Trustee (IDBI Trusteeship Services Limited) that the Debenture Trustee has noted the contents furnished by the Issuer as per Regulation 52(4).

In pursuance thereof we hereby confirm that we have received the aforesaid information through your letter dated November 03, 2018 and we have noted the contents provided therein.

Thanking you,

Yours faithfully

For **IDBI Trusteeship Services Limited**


Authorised Signatory

